Abrdn Healthcare Investors
NYSE:HQHAsset Management
+$0.15 today
- Market cap
- $1.27B
- Beta
- 0.76
- P/E (TTM)
- 4.2
- EPS (TTM)
- $4.72
- Dividend yield
- 11.57%
Volume 0.23M
Average 0.14M
HQH Interest Expense
Cost of servicing the company's debt during the period.
Abrdn Healthcare InvestorsNYSE: HQH
Interest Expense · Q4 FY2025 · quarter ended Sep 2025
Interest expense of $0 in Q4 FY2025
Q4 FY2025 interest expense was $0.
Context
- Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Interest expense increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Interest Expense vs competitors
How HQH compares with its peers on the latest reported figures
- HQH's FY2025 interest expense of $0 is the lowest of the 10 companies compared; the peer median is $91.25M.
- Interest expense amounts to 0.0% of revenue for HQH, versus a peer median of 42.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $187.99B | +137125.6% | +10.2% | 83281.3% | |
| LTM Mar 2026 | $164.11M | -7.2% | +20.2% | 20.5% | |
| LTM Mar 2026 | $126.62M | +5.3% | -88.3% | 51.7% | |
| LTM Mar 2026 | $99.63M | +23.8% | +46.3% | 56.0% | |
| LTM Mar 2026 | $91.25M | +31.8% | +26.1% | 42.0% | |
| LTM Mar 2026 | $87.01M | +29.0% | +33.1% | 31.5% | |
| LTM Mar 2026 | $81.93M | +8.5% | +15.5% | 41.7% | |
KBDCKayne Anderson BDC, Inc. | LTM Mar 2026 | $76.18M | +28.6% | +61.4% | 38.5% |
| LTM Mar 2026 | $32.3M | -1.4% | +19.5% | 43.2% | |
| FY2025 | $0 | — | — | 0.0% | |
| Peer median (excluding HQH) | $91.25M | +23.8% | +20.2% | 42.0% | |
Competitors are the stored peer set for HQH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.48M | 8.27M | 10.29M | 10.77M | 99.81M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 6.48M | 8.27M | 10.29M | 10.77M | 99.81M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 12.71M | 11.94M | 11.48M | 10.99M | 1.14M |
| Operating Expenses | 12.71M | 11.94M | 11.48M | 10.99M | 1.2M |
| Depreciation & Amortization | 6.23M | 3.67M | 1.19M | 220.27K | 0 |
| EBITDA | 0 | 0 | 0 | 0 | 98.61M |
| EBITDA Margin | 0.0% | 0.0% | 0.0% | 0.0% | 98.8% |
| Operating Income | (6.23M) | (3.67M) | (1.19M) | (220.27K) | 98.61M |
| Operating Margin | -96.1% | -44.4% | -11.5% | -2.0% | 98.8% |
| Interest Income | 0 | 112.31K | 620.01K | 2.02M | 1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 161.41M | (190.56M) | 57.52M | 185.17M | 0 |
| Income Before Tax | 155.18M | (194.23M) | 56.33M | 184.95M | 98.61M |
| Pre-Tax Margin | 2394.6% | -2348.4% | 547.4% | 1717.4% | 98.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 155.18M | (194.23M) | 56.33M | 184.95M | 98.61M |
| Net Margin | 2394.6% | -2348.4% | 547.4% | 1717.4% | 98.8% |
| EPS (Basic) | 3.49 | (4.10) | 1.14 | 3.55 | 1.84 |
| EPS (Diluted) | 3.49 | (4.10) | 1.14 | 3.55 | 1.84 |
| Weighted Avg Shares | 45.43M | 47.34M | 49.44M | 52.13M | 53.63M |
| Weighted Avg Shares (Diluted) | 45.43M | 47.34M | 49.44M | 52.13M | 53.63M |
Abrdn Healthcare Investors
NYSE:HQH
Intrinsic Alpha fair value
Locked
Current Price
$22.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.